{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:35:43Z","timestamp":1763037343778,"version":"3.37.3"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0221231","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T17:23:40Z","timestamp":1567185820000},"page":"e0221231","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9655-817X","authenticated-orcid":true,"given":"Ana Bel\u00e9n","family":"P\u00e9rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Chueca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4778-790X","authenticated-orcid":true,"given":"Juan","family":"Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Antonio","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Salmer\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rivero-Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Hidalgo-Tenorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9997-6761","authenticated-orcid":true,"given":"Francisco","family":"T\u00e9llez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Von-Wichmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Omar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Hern\u00e1ndez-Quero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Joaquin","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Collado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Bel\u00e9n","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Garc\u00eda-Deltoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Pascasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"Selfa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Miguel","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"De la Iglesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Ignacio","family":"Arenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Garc\u00eda-Bujalance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"R\u00edos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onofre","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Garc\u00eda-Herola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"V\u00e9lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Rinc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,8,30]]},"reference":[{"key":"pone.0221231.ref001","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl.1","key":"pone.0221231.ref002","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/liv.13638","article-title":"Treatment of hepatitis C: Results in real life","volume":"38","author":"C. H\u00e9zode","year":"2018","journal-title":"Liver International"},{"key":"pone.0221231.ref003","unstructured":"AASLD-IDSA. Recommendations for Testing, Managing, and Treating Hepatitis C. http:\/\/www.hcvguidelines.org. Accessed June 2018."},{"key":"pone.0221231.ref004","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL Recommendations on Treatment of Hepatitis C 2018","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"issue":"8","key":"pone.0221231.ref005","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1073\/pnas.88.8.3392","article-title":"Nucleotide sequence and mutation rate of the H strain of hepatitis C virus","volume":"88","author":"N Ogata","year":"1991","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"journal-title":"HCV Classification","article-title":"International Committee on Taxonomy of Viruses (ICTV).","author":"DB Smith","key":"pone.0221231.ref006"},{"issue":"1","key":"pone.0221231.ref007","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"DB Smith","year":"2014","journal-title":"Hepatology"},{"key":"pone.0221231.ref008","first-page":"121A","article-title":"Identification of Novel HCV Genotype and Subtypes in Patients Treated with Sofosbuvir-Based Regimens. The 68th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2017","volume":"66","author":"C Hedskog","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"pone.0221231.ref009","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"JP Messina","year":"2015","journal-title":"Hepatology"},{"issue":"9","key":"pone.0221231.ref010","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/jvh.12700","article-title":"Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000\u20132015 period (the GEHEP 005 study).","volume":"24","author":"A Aguilera","year":"2017","journal-title":"J Viral Hepat"},{"key":"pone.0221231.ref011","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome","volume":"66","author":"S Zeuzem","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0221231.ref012","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2017.01.050","article-title":"Safety and Efficacy of Elbasvir\/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis","volume":"152","author":"IM Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"pone.0221231.ref013","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S0168-8278(18)30260-5","article-title":"Safety and efficacy of Sofosbuvir\/Velpatasvir with and without Ribavirin in genotype 3HCV-infected patients with cirrhosis","volume":"68","author":"M Buti","year":"2018","journal-title":"Journal of Hepatology"},{"issue":"4","key":"pone.0221231.ref014","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/hep.29256","article-title":"Sofosbuvir-Velpatasvir With Ribavirin for 24 Weeks in Hepatitis C Virus Patients Previously Treated With a Direct-Acting Antiviral Regimen","volume":"66","author":"EJ Gane","year":"2017","journal-title":"Hepatology"},{"key":"pone.0221231.ref015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens","volume":"151","author":"JM Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"pone.0221231.ref016","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"C. Sarrazin","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"pone.0221231.ref017","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1053\/j.gastro.2016.10.017","article-title":"Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir","volume":"152","author":"TE Komatsu","year":"2017","journal-title":"Gastroenterology"},{"issue":"6","key":"pone.0221231.ref018","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/hep.29693","article-title":"Impact of Hepatitis C Virus Polymorphisms on Direct-Acting Antiviral Treatment Efficacy: Regulatory Analyses and Perspectives","volume":"67","author":"PR Harrington","year":"2017","journal-title":"Hepatology"},{"key":"pone.0221231.ref019","first-page":"575A","article-title":"Resistance guided retreatment of patients failing NS5A inhibitors in Spain: real life data from the GEHEP-004 cohort. The 68th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2017","volume":"66","author":"AB P\u00e9rez","year":"2017","journal-title":"Hepatology"},{"key":"pone.0221231.ref020","unstructured":"AEEH\/SEIMC. Gu\u00eda AEEH de tratamiento de la infecci\u00f3n por virus de la hepatitis C 2018. http:\/\/aeeh.es\/wp-content\/uploads\/2018\/07\/GUIA-DE-TRATAMIENTO-VHC-2018.pdf Accessed August 2018."},{"issue":"5","key":"pone.0221231.ref021","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep4.1050","article-title":"Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review.","volume":"1","author":"SR Bartlett","year":"2017","journal-title":"Hepatol Commun"},{"key":"pone.0221231.ref022","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: State of the art summary","volume":"62","author":"E Lontok","year":"2015","journal-title":"Hepatology"},{"key":"pone.0221231.ref023","unstructured":"European Medicines Agency. Technical data of Sofosbuvir\/Velpatasvir (Epclusa\u00ae).http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/004210\/WC500211151.pdf. Accessed June 2018."},{"key":"pone.0221231.ref024","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jcv.2016.05.010","article-title":"New findings in HCV genotype distribution in selected West European, Russian and Israeli regions.","volume":"81","author":"HCV EuResist Study group","year":"2016","journal-title":"J Clin Virol"},{"issue":"12","key":"pone.0221231.ref025","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1093\/jac\/dkx302","article-title":"Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study","volume":"72","author":"V Cento","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"pone.0221231.ref026","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/jmv.25048","article-title":"Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies","volume":"90","author":"M Grandal","year":"2018","journal-title":"J Med Virol"},{"issue":"9","key":"pone.0221231.ref027","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/apt.14592","article-title":"High efficacy of sofosbuvir\/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection","volume":"47","author":"J Von Felden","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0221231.ref028","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir\u2013Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection","volume":"378","author":"S Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0221231.ref029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018","volume":"37","author":"MC Sorbo","year":"2018","journal-title":"Drug Resist Updat"},{"key":"pone.0221231.ref030","unstructured":"GEHEP Guidelines 2018. https:\/\/seimc.org\/grupos-de-estudio\/gehep\/infinstitucional\/junta-directiva\/produccion-cientifica\/documentos-consenso. Accessed July 2018."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0221231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T03:51:16Z","timestamp":1588996276000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0221231"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Kanda","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,8,30]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0221231","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,8,30]]}}}